2021 Q4 Form 10-Q Financial Statement

#000114036121037756 Filed on November 15, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.569M $1.631M
YoY Change 7.47% 41.83%
% of Gross Profit
Research & Development $5.856M $6.613M
YoY Change -8.07% 38.35%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $7.425M $8.244M
YoY Change -5.17% 39.02%
Operating Profit -$8.244M
YoY Change
Interest Expense $204.0K -$276.0K
YoY Change -1120.0% 1280.0%
% of Operating Profit
Other Income/Expense, Net -$276.0K
YoY Change
Pretax Income -$7.221M -$8.520M
YoY Change -8.01% 43.43%
Income Tax
% Of Pretax Income
Net Earnings -$7.221M -$8.520M
YoY Change -8.01% 43.43%
Net Earnings / Revenue
Basic Earnings Per Share -$0.14
Diluted Earnings Per Share -$121.7K -$143.7K
COMMON SHARES
Basic Shares Outstanding 59.34M 59.29M
Diluted Shares Outstanding 59.29M

Balance Sheet

Concept 2021 Q4 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.65M $36.60M
YoY Change 46.09% 12.41%
Cash & Equivalents $39.65M $36.60M
Short-Term Investments
Other Short-Term Assets $2.172M $1.398M
YoY Change -6.38% 5.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $41.82M $38.00M
YoY Change 41.93% 12.15%
LONG-TERM ASSETS
Property, Plant & Equipment $0.00 $18.00K
YoY Change -70.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.000K $22.00K
YoY Change -94.81% -80.0%
Total Long-Term Assets $7.000K $40.00K
YoY Change -94.81% -76.47%
TOTAL ASSETS
Total Short-Term Assets $41.82M $38.00M
Total Long-Term Assets $7.000K $40.00K
Total Assets $41.83M $38.04M
YoY Change 41.31% 11.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.805M $1.917M
YoY Change 39.71% 177.83%
Accrued Expenses $7.163M $6.382M
YoY Change 77.21% 254.56%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.033M $8.299M
YoY Change 67.31% 233.29%
LONG-TERM LIABILITIES
Long-Term Debt $29.05M $19.30M
YoY Change
Other Long-Term Liabilities $0.00 $1.191M
YoY Change -100.0% 5855.0%
Total Long-Term Liabilities $0.00 $20.49M
YoY Change -100.0% 102350.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.033M $8.299M
Total Long-Term Liabilities $0.00 $20.49M
Total Liabilities $39.21M $28.79M
YoY Change 625.19% 1046.97%
SHAREHOLDERS EQUITY
Retained Earnings -$270.7M
YoY Change 12.79%
Common Stock $59.00K
YoY Change 5.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $893.0K $9.249M
YoY Change
Total Liabilities & Shareholders Equity $41.83M $38.04M
YoY Change 41.31% 11.71%

Cashflow Statement

Concept 2021 Q4 2021 Q3
OPERATING ACTIVITIES
Net Income -$7.221M -$8.520M
YoY Change -8.01% 43.43%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$6.951M -$4.998M
YoY Change 28.48% -39.12%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.999M 10.00M
YoY Change
NET CHANGE
Cash From Operating Activities -6.951M -4.998M
Cash From Investing Activities
Cash From Financing Activities 9.999M 10.00M
Net Change In Cash 3.048M 5.002M
YoY Change -156.34% -160.93%
FREE CASH FLOW
Cash From Operating Activities -$6.951M -$4.998M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1302500
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1302500
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1302500
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1302500
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001133416
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherAssetsNoncurrent
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#AccruedLiabilitiesCurrent
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-31791
dei Entity Registrant Name
EntityRegistrantName
GALECTIN THERAPEUTICS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3562325
dei Entity Address Address Line1
EntityAddressAddressLine1
4960 Peachtree Industrial Blvd.
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 240
dei Entity Address City Or Town
EntityAddressCityOrTown
Norcross
dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30071
dei City Area Code
CityAreaCode
678
dei Local Phone Number
LocalPhoneNumber
620 -3186
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
GALT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
59341305
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-166000
CY2020Q3 us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
-338000
us-gaap Derivative Instruments Not Designated As Hedging Instruments Gain Loss Net
DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
0
CY2021Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
37000
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
12000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
104000
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
72000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
20000000
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
us-gaap Stock Issued1
StockIssued1
104000
us-gaap Stock Issued1
StockIssued1
137000
galt Fair Value Of Derivative Related To Related Party Convertible Note Payable
FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable
853000
galt Fair Value Of Derivative Related To Related Party Convertible Note Payable
FairValueOfDerivativeRelatedToRelatedPartyConvertibleNotePayable
0
galt Reclassification Of Accrued Bonus To Additional Paid In Capital
ReclassificationOfAccruedBonusToAdditionalPaidInCapital
60000
galt Reclassification Of Accrued Bonus To Additional Paid In Capital
ReclassificationOfAccruedBonusToAdditionalPaidInCapital
0
galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
39000
galt Temporary Equity Dividends
TemporaryEquityDividends
-26000
galt Stock Issued During Period Value Warrants And Options Exercised
StockIssuedDuringPeriodValueWarrantsAndOptionsExercised
219000
galt Convertible Preferred Stock Dividends
ConvertiblePreferredStockDividends
38000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3864000
galt Stock Issued During Period Value Warrants And Options Exercised
StockIssuedDuringPeriodValueWarrantsAndOptionsExercised
2951000
CY2021Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
10000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36600000
CY2020Q4 galt Accrued Research And Development Costs And Other Current
AccruedResearchAndDevelopmentCostsAndOtherCurrent
3087000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
127000
CY2021Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3346200000
CY2021Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2401668
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.71
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
44000
CY2021Q3 galt Accrued Research And Development Costs And Other Current
AccruedResearchAndDevelopmentCostsAndOtherCurrent
5716000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
122000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
520000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
789000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6382000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4042000
CY2019Q1 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
10000000
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2019Q2 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2500000
CY2021Q3 us-gaap Lines Of Credit Current
LinesOfCreditCurrent
0
CY2019Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
696000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
65000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
65000
CY2021Q3 us-gaap Line Of Credit
LineOfCredit
0
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
587000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
408000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1422000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1232000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3987575
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.29
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2260000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.31
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
396664
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.35
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1190350
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.18
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4660561
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2260000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
396664
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0058
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0126
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.98
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19800825
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
17036203
galt Contract Cancelation Notice Period
ContractCancelationNoticePeriod
P30D
galt Number Of Operating Leases
NumberOfOperatingLeases
1
CY2021Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P38M
galt Free Rent Period
FreeRentPeriod
P2M
CY2021Q3 us-gaap Security Deposit
SecurityDeposit
6000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
18000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
19000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
12000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
8000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
20000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
19000
CY2021Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1104

Files In Submission

Name View Source Status
0001140361-21-037756-index-headers.html Edgar Link pending
0001140361-21-037756-index.html Edgar Link pending
0001140361-21-037756.txt Edgar Link pending
0001140361-21-037756-xbrl.zip Edgar Link pending
brhc10029958_10q.htm Edgar Link pending
brhc10029958_10q_htm.xml Edgar Link completed
brhc10029958_ex31-1.htm Edgar Link pending
brhc10029958_ex31-2.htm Edgar Link pending
brhc10029958_ex32-1.htm Edgar Link pending
brhc10029958_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
galt-20210930.xsd Edgar Link pending
galt-20210930_cal.xml Edgar Link unprocessable
galt-20210930_def.xml Edgar Link unprocessable
galt-20210930_lab.xml Edgar Link unprocessable
galt-20210930_pre.xml Edgar Link unprocessable
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending